Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.36 |
| ▸ | CA2 | P00918 | 10/20 | 0.36 |
| ▸ | CA9 | Q16790 | 8/20 | 0.36 |
| ▸ | CA12 | O43570 | 7/20 | 0.36 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934037 | 0.88 | CA1 (0.35) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL24242829 | 0.88 | CA1 (0.35) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL12855832 | 0.88 | CA1 (0.35) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL12855792 | 0.88 | CA1 (0.35) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL1140405 | 0.87 | CA1 (0.34) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL1140126 | 0.87 | CA1 (0.34) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL1139917 | 0.83 | CA1 (0.39) | CA1CA2CA9CA12DRD2 | |
| SCHEMBL1139205 | 0.82 | PPM1D (0.35) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL1139948 | 0.82 | PPM1B (0.38) | CA1CA2CA9CA12PPM1D | |
| SCHEMBL1140236 | 0.82 | PPM1B (0.38) | CA1CA2CA9CA12PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | CA1 2621/4885CA2 1983/4885CA9 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.